Welcome to BioSeeker Group!

Orphan Drugs in Oncology Drug Pipeline Update

Additional Information

Published Date Aug 4, 2016
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group
Product Line View All Available Drug Pipeline Update Reports

Availability: In stock

$2,250.00

Quick Overview

BioSeeker Group have identified 476 companies plus partners who are today developing 665 orphan drugs in oncology drugs in 4085 developmental projects in cancer across 422 different targets. In addition, there are 15 suspended drugs and another 190 drugs where development has been ceased.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Orphan Drugs in Oncology Drug Pipeline Update.

    To find out more about Orphan Drugs in Oncology Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Orphan Drugs in Oncology Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or
Extra value: One year of free online updates included with this product

Executive Summary

BioSeeker Group have identified 476 companies plus partners who are today developing 665 orphan drugs in oncology drugs in 4085 developmental projects in cancer across 422 different targets. In addition, there are 15 suspended drugs and another 190 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the Orphan Drugs in Oncology Drug Pipeline Update will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work

Our software lets you define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.


The following short video playlist demonstrates the use of the filter sections, how you can make an inclusion and exclusion search and what to expect from a drug profile result.


Some facts about Orphan Drugs in Oncology Drug Pipeline Update

This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. This designation will in many countries provide several years of marketing exclusivity if the product candidate is approved for the designated orphan indication. It also provides special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of applying for marketing approval.
There are today 476 companies plus partners developing 665 orphan drugs in oncology drugs in 4085 developmental projects in cancer. In addition, there are 15 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 190 drugs. Orphan Drugs In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 422 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 404 out of the 407 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 79 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Details from Orphan Drugs in Oncology Drug Pipeline Update at a glance

This short overview shows actual findings from the Orphan Drugs in Oncology Drug Pipeline Update report.

Companies Includes more than 476 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 665 orphan drugs in oncology drugs in development, which have a total of 4085 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 170
Pre-registration# 22
Phase III# 190
Phase II# 413
Phase I# 296
Preclinical# 133
No Data# 128
Suspended# 15
Ceased# 190

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included orphan drugs in oncology drugs are also in development for 458 other indications, where of 238 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 404 out of the 407 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 314 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 6208 structures available today among drug targets.

Identified drugs are linked to more than 422 different targets, divided into 79 classifications of molecular function:
- Aminopeptidase activity
- ATPase activity
- Auxiliary transport protein activity
- Carboxy-lyase activity
- Carboxypeptidase activity
- Caspase activator activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Chromatin binding
- Cofactor binding
- Complement activity
- Cysteine-type peptidase activity
- Cytokine activity
-
- Cytoskeletal protein binding
- Deacetylase activity
- Deaminase activity
- DNA binding
- DNA repair protein
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- DNA-directed RNA polymerase activity
- DNA-methyltransferase activity
- Extracellular ligand-gated ion channel activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Glutathione transferase activity
- Growth factor activity
- GTPase activity
- Guanylate cyclase activity
- Heat shock protein activity
- Hydrolase activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid kinase activity
- Lipid phosphatase activity
- Metallopeptidase activity
- Methyltransferase activity
- MHC class I receptor activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Peptide hormone
- Peroxidase activity
- Phosphoric diester hydrolase activity
- Phosphorylase activity
- Protease inhibitor activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine phosphatase activity
- Protein tyrosine/serine/threonine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- Receptor signaling protein tyrosine phosphatase activity
- RNA binding
- RNA-directed DNA polymerase activity
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Superoxide dismutase activity
- T cell receptor activity
- T cell receptor binding
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
- Voltage-gated ion channel activity

Sub-Cellular Localization
Identified targets are categorized into 32 different primary and alternate sub-cellular localizations:
- Cell surface
- Centrosome
- Chromosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Golgi apparatus
- Integral to membrane
- Intermediate filament
- Kinetochore
- Lysosome
- Membrane fraction
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisome
- Plasma membrane
- Sarcoplasmic reticulum
- Secreted
- Secretory granule
- Secretory vesicle
- Soluble fraction

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 597 protein expression profiles of 379 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 257 Pathways
- KEGG# 214 Pathways
- NCI-Nature# 253 Pathways
- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

Orphan Drugs in Oncology Drug Pipeline Update provides you with a profile for each identified drug.
Click here for a short video (6m 12s) showing a typical drug profile

A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Company & Partners Presentation of principal Company and partners.
Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions
Analyst comments
Deals and Licensing Collaborations and deals
Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available Preclinical data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data., developmental history and scientific data.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twenty-four different parameters, all of which can be used as inclusion or exclusion parameters, plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report of a selection of drugs that match your criteria.


Application Features Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
Click here for a short video (6m12s) showing a typical drug profile

System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Orphan Drugs in Oncology Drug Pipeline Update.
    To find out more about Orphan Drugs in Oncology Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Orphan Drugs in Oncology Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drugs' category:


FSH Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 273 companies plus partners who are today developing 369 FSH pathway targeting drugs in 1441 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 167 drugs where development has been ceased. Learn More


Brain Cancer Drug Pathway Analyzer
There are today at least 332 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways for the treatment of brain cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 235 drug targets that are included in this drug-pathway analyzing tool. No less than 229 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


Wnt Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More


p53 Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 120 companies plus partners who are today developing 108 p53 signaling pathway targeting drugs in 340 developmental projects in cancer across 84 different targets. In addition, there is 1 suspended drug and another 67 drugs where development has been ceased. Learn More

Other selected research from the 'R&D' category:


IL-6 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More


Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 248 companies plus partners who are today developing 346 Kit receptor pathway targeting drugs in 1506 developmental projects in cancer across 178 different targets. In addition, there are 3 suspended drugs and another 176 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Learn More


Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More